Show simple item record

AuthorAltarawneh, Heba N
AuthorChemaitelly, Hiam
AuthorAyoub, Houssein H
AuthorTang, Patrick
AuthorHasan, Mohammad R
AuthorYassine, Hadi M
AuthorAl-Khatib, Hebah A
AuthorSmatti, Maria K
AuthorCoyle, Peter
AuthorAl-Kanaani, Zaina
AuthorAl-Kuwari, Einas
AuthorJeremijenko, Andrew
AuthorKaleeckal, Anvar H
AuthorLatif, Ali N
AuthorShaik, Riyazuddin M
AuthorAbdul-Rahim, Hanan F
AuthorNasrallah, Gheyath K
AuthorAl-Kuwari, Mohamed G
AuthorButt, Adeel A
AuthorAl-Romaihi, Hamad E
AuthorAl-Thani, Mohamed H
AuthorAl-Khal, Abdullatif
AuthorBertollini, Roberto
AuthorAbu-Raddad, Laith J
Available date2022-06-20T10:40:30Z
Publication Date2022-06-15
Publication NameNew England Journal of Medicine
Identifierhttp://dx.doi.org/10.1056/NEJMoa2203965
CitationAltarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, Al-Khatib HA, Smatti MK, Coyle P, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMoa2203965.
ISSN0028-4793
URIhttp://hdl.handle.net/10576/32147
AbstractThe protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) variant is unclear. We conducted a national, matched, test-negative, case-control study in Qatar from December 23, 2021, through February 21, 2022, to evaluate the effectiveness of vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), natural immunity due to previous infection with variants other than omicron, and hybrid immunity (previous infection and vaccination) against symptomatic omicron infection and against severe, critical, or fatal coronavirus disease 2019 (Covid-19). The effectiveness of previous infection alone against symptomatic BA.2 infection was 46.1% (95% confidence interval [CI], 39.5 to 51.9). The effectiveness of vaccination with two doses of BNT162b2 and no previous infection was negligible (-1.1%; 95% CI, -7.1 to 4.6), but nearly all persons had received their second dose more than 6 months earlier. The effectiveness of three doses of BNT162b2 and no previous infection was 52.2% (95% CI, 48.1 to 55.9). The effectiveness of previous infection and two doses of BNT162b2 was 55.1% (95% CI, 50.9 to 58.9), and the effectiveness of previous infection and three doses of BNT162b2 was 77.3% (95% CI, 72.4 to 81.4). Previous infection alone, BNT162b2 vaccination alone, and hybrid immunity all showed strong effectiveness (>70%) against severe, critical, or fatal Covid-19 due to BA.2 infection. Similar results were observed in analyses of effectiveness against BA.1 infection and of vaccination with mRNA-1273. No discernable differences in protection against symptomatic BA.1 and BA.2 infection were seen with previous infection, vaccination, and hybrid immunity. Vaccination enhanced protection among persons who had had a previous infection. Hybrid immunity resulting from previous infection and recent booster vaccination conferred the strongest protection. (Funded by Weill Cornell Medicine-Qatar and others.).
Languageen
PublisherMassachusetts Medical Society
SubjectCOVID-19
Omicron Infections
Vaccination
TitleEffects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
TypeArticle
ESSN1533-4406
dc.accessType Full Text


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record